;PMID: 9606006
;source_file_2906.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:38..124] = [t:38..124]
;2)section:[e:128..151] = [t:128..151]
;3)section:[e:155..230] = [t:155..230]
;4)sentence:[e:234..320] = [t:234..320]
;5)sentence:[e:321..494] = [t:321..494]
;6)sentence:[e:495..595] = [t:495..595]
;7)sentence:[e:596..768] = [t:596..768]
;8)sentence:[e:769..1061] = [t:769..1061]
;9)sentence:[e:1062..1202] = [t:1062..1202]
;10)sentence:[e:1203..1401] = [t:1203..1401]
;11)section:[e:1405..1449] = [t:1405..1449]

;section 0 Span:0..32
;J Drug Target.  1998;5(3):163-9.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Drug) (NNP:[7..13] Target) (.:[13..14] .)
        (CD:[16..21] 1998;) (CD:[21..22] 5) (NN:[22..23] -LRB-) (CD:[23..24] 3)
        (-RRB-:[24..25] -RRB-) (CD:[25..29] :163) (::[29..30] -)
        (CD:[30..32] 9.)))

;sentence 1 Span:38..124
;Nuclear localization signal peptides enhance cationic liposome-mediated gene 
;therapy.
;[38..65]:gene-protein:"Nuclear localization signal"
(SENT
  (S-HLN
    (NP-SBJ
      (NML (JJ:[38..45] Nuclear) (NN:[46..58] localization) (NN:[59..65] signal))
      (NNS:[66..74] peptides))
    (VP (VBP:[75..82] enhance)
      (NP (JJ:[83..91] cationic)
        (ADJP (NN:[92..100] liposome) (HYPH:[100..101] -)
              (VBN:[101..109] mediated))
        (NN:[110..114] gene) (NN:[116..123] therapy)))
    (.:[123..124] .)))

;section 2 Span:128..151
;Aronsohn AI, Hughes JA.
(SEC
  (FRAG (NNP:[128..136] Aronsohn) (NNP:[137..139] AI) (,:[139..140] ,)
        (NNP:[141..147] Hughes) (NNP:[148..150] JA) (.:[150..151] .)))

;section 3 Span:155..230
;Department of Pharmaceutics, University of Florida, Gainesville 32610, USA.
(SEC
  (FRAG (NNP:[155..165] Department) (IN:[166..168] of)
        (NNP:[169..182] Pharmaceutics) (,:[182..183] ,)
        (NNP:[184..194] University) (IN:[195..197] of) (NNP:[198..205] Florida)
        (,:[205..206] ,) (NNP:[207..218] Gainesville) (CD:[219..224] 32610)
        (,:[224..225] ,) (NNP:[226..229] USA) (.:[229..230] .)))

;sentence 4 Span:234..320
;The use of genes as therapeutic drugs will likely involve non-viral delivery 
;systems.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[234..237] The) (NN:[238..241] use))
      (PP (IN:[242..244] of)
        (NP (NNS:[245..250] genes)))
      (PP (IN:[251..253] as)
        (NP (JJ:[254..265] therapeutic) (NNS:[266..271] drugs))))
    (VP (MD:[272..276] will)
      (ADVP (RB:[277..283] likely))
      (VP (VB:[284..291] involve)
        (NP
          (ADJP (AFX:[292..295] non) (HYPH:[295..296] -) (JJ:[296..301] viral))
          (NN:[302..310] delivery) (NNS:[312..319] systems))))
    (.:[319..320] .)))

;sentence 5 Span:321..494
;While traditionally less effective for gene expression, the advantages  of a
;non-viral delivery system include ease of production, lower toxicity, and  no
;risk of infection.
(SENT
  (S
    (PP (IN:[321..326] While)
      (NP
        (NP (RB:[327..340] traditionally) (RBR:[341..345] less)
            (JJ:[346..355] effective))
        (PP (IN:[356..359] for)
          (NP (NN:[360..364] gene) (NN:[365..375] expression)))))
    (,:[375..376] ,)
    (NP-SBJ
      (NP (DT:[377..380] the) (NNS:[381..391] advantages))
      (PP (IN:[393..395] of)
        (NP (DT:[396..397] a)
          (ADJP (AFX:[398..401] non) (HYPH:[401..402] -) (JJ:[402..407] viral))
          (NN:[408..416] delivery) (NN:[417..423] system))))
    (VP (VBP:[424..431] include)
      (NP
        (NP
          (NP (NN:[432..436] ease))
          (PP (IN:[437..439] of)
            (NP (NN:[440..450] production))))
        (,:[450..451] ,)
        (NP (JJR:[452..457] lower) (NN:[458..466] toxicity))
        (,:[466..467] ,) (CC:[468..471] and)
        (NP
          (NP (DT:[473..475] no) (NN:[476..480] risk))
          (PP (IN:[481..483] of)
            (NP (NN:[484..493] infection))))))
    (.:[493..494] .)))

;sentence 6 Span:495..595
;However, most non-viral systems do not incorporate a  mechanism for gene
;transport into the nucleus.
(SENT
  (S
    (ADVP (RB:[495..502] However))
    (,:[502..503] ,)
    (NP-SBJ (JJS:[504..508] most)
      (ADJP (AFX:[509..512] non) (HYPH:[512..513] -) (JJ:[513..518] viral))
      (NNS:[519..526] systems))
    (VP (VBP:[527..529] do) (RB:[530..533] not)
      (VP (VB:[534..545] incorporate)
        (NP
          (NP (DT:[546..547] a) (NN:[549..558] mechanism))
          (PP (IN:[559..562] for)
            (NP
              (NP (NN:[563..567] gene) (NN:[568..577] transport))
              (PP (IN:[578..582] into)
                (NP (DT:[583..586] the) (NN:[587..594] nucleus))))))))
    (.:[594..595] .)))

;sentence 7 Span:596..768
;Nuclear localization signal  peptides can combine the increased expression of
;viral delivery systems with the  safety and ease of preparation of non-viral
;delivery systems.
;[596..623]:gene-protein:"Nuclear localization signal"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[596..603] Nuclear) (NN:[604..616] localization)
           (NN:[617..623] signal))
      (NNS:[625..633] peptides))
    (VP (MD:[634..637] can)
      (VP (VB:[638..645] combine)
        (NP
          (NP (DT:[646..649] the) (VBN:[650..659] increased)
              (NN:[660..670] expression))
          (PP (IN:[671..673] of)
            (NP (JJ:[674..679] viral) (NN:[680..688] delivery)
                (NNS:[689..696] systems)))
          (PP (IN:[697..701] with)
            (NP
              (NP (DT:[702..705] the) (NN:[707..713] safety) (CC:[714..717] and)
                  (NN:[718..722] ease))
              (PP (IN:[723..725] of)
                (NP
                  (NP (NN:[726..737] preparation))
                  (PP (IN:[738..740] of)
                    (NP
                      (ADJP (AFX:[741..744] non) (HYPH:[744..745] -)
                            (JJ:[745..750] viral))
                      (NN:[751..759] delivery) (NNS:[760..767] systems))))))))))
    (.:[767..768] .)))

;sentence 8 Span:769..1061
;A novel non-viral  delivery vehicle consisting of a conglomerate of a
;synthetic nuclear  localization signal peptide derived from the SV40 virus, a
;luciferase encoding  PGL3 plasmid, and a cationic lipid DOTAP:DOPE (1:1 w/w)
;liposome was transfected  into SKnSH mammalian neuroblastoma cells.
;[849..877]:gene-protein:"nuclear  localization signal"
;[917..927]:gene-protein:"luciferase"
;[1041..1060]:malignancy-type:"neuroblastoma cells"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[769..770] A) (JJ:[771..776] novel)
        (ADJP (AFX:[777..780] non) (HYPH:[780..781] -) (JJ:[781..786] viral))
        (NN:[788..796] delivery) (NN:[797..804] vehicle))
      (VP (VBG:[805..815] consisting)
        (PP-CLR (IN:[816..818] of)
          (NP
            (NP (DT:[819..820] a) (NN:[821..833] conglomerate))
            (PP (IN:[834..836] of)
              (NP
                (NP (DT:[837..838] a) (JJ:[839..848] synthetic)
                  (NML (JJ:[849..856] nuclear) (NN:[858..870] localization)
                       (NN:[871..877] signal))
                  (NN:[878..885] peptide))
                (VP (VBN:[886..893] derived)
                  (NP (-NONE-:[893..893] *))
                  (PP (IN:[894..898] from)
                    (NP
                      (NP
                        (NP (DT:[899..902] the) (NN:[903..907] SV40)
                            (NN:[908..913] virus))
                        (,:[913..914] ,)
                        (NP
                          (NP (DT:[915..916] a) (NN:[917..927] luciferase))
                          (VP (VBG:[928..936] encoding)
                            (NP (NN:[938..942] PGL3) (NN:[943..950] plasmid)))))
                      (,:[950..951] ,) (CC:[952..955] and)
                      (NP (DT:[956..957] a) (JJ:[958..966] cationic)
                          (NN:[967..972] lipid)
                        (NML (NN:[973..978] DOTAP) (SYM:[978..979] :)
                             (NN:[979..983] DOPE)
                          (PRN (-LRB-:[984..985] -LRB-)
                            (FRAG (CD:[985..986] 1) (SYM:[986..987] :)
                                  (CD:[987..988] 1) (NN:[989..990] w)
                                  (SYM:[990..991] /) (NN:[991..992] w))
                            (-RRB-:[992..993] -RRB-)))
                        (NN:[994..1002] liposome)))))))))))
    (VP (VBD:[1003..1006] was)
      (VP (VBN:[1007..1018] transfected)
        (NP-1 (-NONE-:[1018..1018] *))
        (PP (IN:[1020..1024] into)
          (NP (NN:[1025..1030] SKnSH) (JJ:[1031..1040] mammalian)
             (NN:[1041..1054] neuroblastoma) (NNS:[1055..1060] cells)))))
    (.:[1060..1061] .)))

;sentence 9 Span:1062..1202
;A three-fold increase in luciferase  expression was seen with the delivery
;system containing a NLS peptide over  cationic liposome controls.
;[1087..1097]:gene-protein:"luciferase"
;[1157..1160]:gene-protein:"NLS"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1062..1063] A)
        (QP (CD:[1064..1069] three) (HYPH:[1069..1070] -) (JJ:[1070..1074] fold))
        (NN:[1075..1083] increase))
      (PP (IN:[1084..1086] in)
        (NP (NN:[1087..1097] luciferase) (NN:[1099..1109] expression))))
    (VP (VBD:[1110..1113] was)
      (VP (VBN:[1114..1118] seen)
        (NP-1 (-NONE-:[1118..1118] *))
        (PP (IN:[1119..1123] with)
          (NP
            (NP (DT:[1124..1127] the) (NN:[1128..1136] delivery)
                (NN:[1137..1143] system))
            (VP (VBG:[1144..1154] containing)
              (NP
                (NP (DT:[1155..1156] a) (NN:[1157..1160] NLS)
                    (NN:[1161..1168] peptide))
                (PP (IN:[1169..1173] over)
                  (NP (JJ:[1175..1183] cationic) (NN:[1184..1192] liposome)
                      (NNS:[1193..1201] controls)))))))))
    (.:[1201..1202] .)))

;sentence 10 Span:1203..1401
;Examination of the factors that limit the rate of  transgene expression can
;potentially lead to the discovery of new ways to  improve the efficiency and
;efficacy of nonviral methods of gene therapy.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1203..1214] Examination))
      (PP (IN:[1215..1217] of)
        (NP
          (NP (DT:[1218..1221] the) (NNS:[1222..1229] factors))
          (SBAR
            (WHNP-1 (WDT:[1230..1234] that))
            (S
              (NP-SBJ-1 (-NONE-:[1234..1234] *T*))
              (VP (VBP:[1235..1240] limit)
                (NP
                  (NP (DT:[1241..1244] the) (NN:[1245..1249] rate))
                  (PP (IN:[1250..1252] of)
                    (NP (NN:[1254..1263] transgene) (NN:[1264..1274] expression))))))))))
    (VP (MD:[1275..1278] can)
      (ADVP (RB:[1279..1290] potentially))
      (VP (VB:[1291..1295] lead)
        (PP-CLR (TO:[1296..1298] to)
          (NP
            (NP (DT:[1299..1302] the) (NN:[1303..1312] discovery))
            (PP (IN:[1313..1315] of)
              (NP
                (NP (JJ:[1316..1319] new) (NNS:[1320..1324] ways))
                (SBAR
                  (WHNP-2 (-NONE-:[1324..1324] 0))
                  (S
                    (NP-SBJ-2 (-NONE-:[1324..1324] *T*))
                    (VP (TO:[1325..1327] to)
                      (VP (VB:[1329..1336] improve)
                        (NP
                          (NP (DT:[1337..1340] the) (NN:[1341..1351] efficiency)
                              (CC:[1352..1355] and) (NN:[1356..1364] efficacy))
                          (PP (IN:[1365..1367] of)
                            (NP
                              (NP (JJ:[1368..1376] nonviral)
                                  (NNS:[1377..1384] methods))
                              (PP (IN:[1385..1387] of)
                                (NP (NN:[1388..1392] gene)
                                    (NN:[1393..1400] therapy))))))))))))))))
    (.:[1400..1401] .)))

;section 11 Span:1405..1449
;PMID: 9606006 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1405..1409] PMID) (::[1409..1410] :) (CD:[1411..1418] 9606006)
        (NN:[1419..1420] -LSB-) (NNP:[1420..1426] PubMed) (::[1427..1428] -)
        (NN:[1429..1436] indexed) (IN:[1437..1440] for)
        (NNP:[1441..1449] MEDLINE-RSB-)))
